-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 28, ImmuneOnco announced that the world's first dual-target antibody-receptor recombinant protein drug targeting human CD47 x Her2 (IMM2902) has been accepted by the US FDA for a new drug clinical research application (IND)
IMM2902 targets the immunomodulatory targets CD47 and Her2, and inhibits tumor cell growth by accelerating the endocytosis and degradation of Her2; it stimulates the phagocytosis of tumor cells by macrophages by blocking the "don't eat me" signal and activating the "eat me" signal, And present the phagocytosed tumor antigen to T cells, thus exerting a powerful tumor immunotherapy effect
The product pipeline of ImmuneOnco, sourced from the official website of ImmuneOnco